Advertisement
Screener

Voyager Therapeutics, Inc. (VYGR) Graph

VYGR Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue $3.17M; Research and development $22.04M; Operating expenses $29.56M; Income tax $20.00K.
  • 2026-03-31: Revenue $2.59M; Research and development $24.60M; Operating expenses $32.86M; Income tax $14.00K.
  • 2025-12-31: Revenue $15.34M*; Research and development $35.95M*; Operating expenses $45.27M*; Income tax $9.00K*.
  • 2025-09-30: Revenue $13.37M; Research and development $35.87M; Operating expenses $43.96M; Income tax $83.00K.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$3.17M$22.04M$29.56M$20.00K-$24.47M
2026-03-31$2.59M$24.60M$32.86M$14.00K-$27.94M
2025-12-31$15.34M*$35.95M*$45.27M*$9.00K*-$27.43M*
2025-09-30$13.37M$35.87M$43.96M$83.00K-$27.89M
2025-06-30$5.20M$31.33M$41.83M$15.00K-$33.38M
2025-03-31$6.47M$31.53M$41.17M$37.00K-$31.02M
2024-09-30$24.63M$30.24M$38.41M$43.00K-$9.04M
2024-06-30$29.58M$34.45M$44.60M$24.00K-$10.14M
2024-03-31$19.52M$27.09M$35.70M$14.00K-$11.33M
2023-09-30$4.61M$25.86M$34.12M-$177.00K-$25.90M
2023-06-30$4.85M$21.98M$30.28M$59.00K-$22.21M
2023-03-31$150.48M$18.57M$27.60M$704.00K$124.04M
2022-09-30$41.09M$19.34M$26.64M(m)$17.62M
2022-06-30$712.00K$12.53M$20.08M(m)-$19.09M
2022-03-31$658.00K$14.35M$22.01M(m)-$21.32M
2021-09-30$1.48M$17.91M$26.63M(m)-$25.14M
2021-06-30$1.36M$19.50M$29.94M(m)-$30.12M
2021-03-31$6.50M$22.35M$32.09M(m)-$21.65M
2020-09-30$117.84M$25.04M$33.32M(m)$85.61M
2020-06-30$28.68M$29.42M$37.66M(m)-$8.68M
2020-03-31$18.07M$32.29M$42.50M(m)-$24.26M
2019-12-31$32.67M(m)$46.44M(m)-$12.57M
2019-09-30$20.43M$29.78M$38.24M(m)-$15.01M
2019-06-30$46.09M$28.58M$36.90M(m)$11.15M
2019-03-31$5.20M$24.83M$34.49M(m)-$27.17M
2018-12-31$2.01M(m)$25.17M(m)-$22.53M
2018-09-30$2.09M$16.63M$23.24M(m)-$20.29M
2018-06-30$2.58M$16.51M$28.27M(m)-$25.54M
2018-03-31$942.00K$14.85M$22.04M-$180.00K-$19.93M
2017-12-31$6.35M(m)$18.69M(m)-$11.83M
2017-09-30$1.15M$19.56M$24.50M(m)-$23.35M
2017-06-30$1.18M$15.30M$19.82M$195.00K-$18.88M
2017-03-31$1.46M$14.07M$18.99M-$226.00K-$16.65M
2016-12-31$2.36M(m)$16.20M(m)(m)
2016-09-30$3.31M$10.31M$13.68M-$303.00K-$9.00M
2016-06-30$3.72M$10.48M$13.34M(m)-$9.34M
2016-03-31$4.83M$8.73M$12.30M(m)-$7.19M
2015-12-31$4.94M(m)$12.38M(m)(m)
2015-09-30$4.94M$6.48M$8.96M(m)-$3.92M
2015-06-30$4.88M$6.46M$8.85M(m)-$3.90M
2015-03-31$2.58M$5.52M$7.40M(m)-$14.58M
2014-12-31(m)(m)$4.50M(m)(m)
2014-09-30(m)$2.40M$3.66M(m)-$4.00M
2014-06-30(m)(m)$3.23M(m)(m)
2014-03-31(m)(m)$2.98M(m)(m)

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$5.76M$46.64M$62.42M$34.00K-$52.41M
2025-06-30$11.67M$62.86M$82.99M$52.00K-$64.40M
2024-06-30$49.09M$61.54M$80.30M$38.00K-$21.47M
2023-06-30$155.33M$40.55M$57.88M$763.00K$101.84M
2022-06-30$1.37M$26.88M$42.09M(m)-$40.41M
2021-06-30$7.86M$41.85M$62.03M(m)-$51.77M
2020-06-30$46.75M$61.72M$80.16M(m)-$32.94M
2019-06-30$51.28M$53.41M$71.39M(m)-$16.02M
2018-06-30$3.52M$31.36M$50.30M-$180.00K-$45.47M
2017-06-30$2.64M$29.37M$38.80M-$31.00K-$35.52M
2016-06-30$8.55M$19.22M$25.64M(m)-$16.52M
2015-06-30$7.46M$11.98M$16.25M(m)-$18.47M
2013-12-31(m)$2.32M$3.77M(m)(m)

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$25.04M$98.72M$126.95M$135.00K-$92.30M
2024-09-30$73.72M$91.78M$118.71M$81.00K-$30.52M
2023-09-30$159.95M$66.42M$92.00M$586.00K$75.94M
2022-09-30$42.46M$46.21M$68.73M(m)-$22.78M
2021-09-30$9.34M$59.77M$88.66M(m)-$76.91M
2020-09-30$164.59M$86.76M$113.48M(m)$52.67M
2019-09-30$71.72M$83.18M$109.63M(m)-$31.02M
2018-09-30$5.61M$47.99M$73.55M-$180.00K-$65.76M
2017-09-30$3.79M$48.93M$63.30M-$31.00K-$58.87M
2016-09-30$11.86M$29.53M$39.31M-$303.00K-$25.52M
2015-09-30$12.40M$18.46M$25.21M(m)-$22.39M
2014-09-30(m)$5.94M$9.87M(m)-$11.63M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$40.37M$134.67M$172.22M$144.00K-$119.72M
2024-12-31$80.00M$127.37M$163.29M$665.00K-$65.00M
2023-12-31$250.01M$92.17M$127.99M$1.41M$132.33M
2022-12-31$40.91M$60.76M$91.74M$16.00K-$46.41M
2021-12-31$37.41M$73.79M$111.03M(m)-$71.20M
2020-12-31$171.13M$108.75M$143.74M(m)$36.74M
2019-12-31$104.39M$119.73M$156.07M(m)-$43.60M
2018-12-31$7.62M$64.91M$98.71M-$180.00K-$88.29M
2017-12-31$10.13M$62.26M$82.00M(m)-$70.70M
2016-12-31$14.22M$42.25M$55.52M$52.00K-$40.19M
2015-12-31$17.33M$27.68M$37.59M$0.00-$29.67M
2014-12-31(m)$8.90M$14.37M(m)-$16.32M

Similar stocks

Stock NameCountryMarket CapPE Ratio
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79